Mania News and Research RSS Feed - Mania News and Research

Rare inherited gene mutations may contribute to severe forms of bipolar disorder

Rare inherited gene mutations may contribute to severe forms of bipolar disorder

Using so-called next-generation genome sequencing, researchers at Johns Hopkins have identified 84 potential inherited gene mutations that may contribute to the most severe forms of bipolar disorder. About 5.6 million Americans are estimated to have bipolar disorder. [More]
Study demonstrates effectiveness of NeuroStar TMS Therapy System in women with postpartum depression

Study demonstrates effectiveness of NeuroStar TMS Therapy System in women with postpartum depression

An unfortunate fact facing mothers in the U.S. is that postpartum depression is the most common complication of childbirth. Approximately 10 to 15 percent of women who give birth each year – or roughly 600,000 women – experience postpartum depression symptoms. [More]
Magic mushroom compound may offer potential new way for antidepressant research

Magic mushroom compound may offer potential new way for antidepressant research

Psilocybin – a hallucinogenic compound derived from magic mushrooms – may offer a possible new avenue for antidepressant research, according to a new study published in The Lancet Psychiatry today. [More]
Depression, anxiety co-occur in bipolar disorder patients following mania

Depression, anxiety co-occur in bipolar disorder patients following mania

Adults with bipolar disorder are just as likely to develop anxiety as depression following an episode of mania, according to data from a national survey of more than 34,000 adults. This finding, published today in Molecular Psychiatry, may expand our understanding of bipolar disorder to include anxiety. [More]
FDA proposes to change regulation of ECT treatment

FDA proposes to change regulation of ECT treatment

For decades, people with severe depression, bipolar disorder, and other major mental health conditions have gotten help from the treatment known as ECT, when nothing else helped them. [More]
Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. [More]
Commercialization of health and beauty can lead to Angelina Jolie syndrome

Commercialization of health and beauty can lead to Angelina Jolie syndrome

The politicization and commercialization of health issues in today's Western culture have led to growing healthism -- a peremptory idea of self-preserving behaviour. This approach criticizes everything that fails to fit into the glamorous standards of a beautiful, young and slim body. [More]
Groundbreaking study establishes empirical biomarkers to aid in diagnosis, treatment of psychosis

Groundbreaking study establishes empirical biomarkers to aid in diagnosis, treatment of psychosis

In a groundbreaking study led by UT Southwestern Medical Center, a comprehensive set of empirical biomarkers has been established to aid in diagnosis and treatment of psychosis. [More]
Mayo Clinic investigators discover potential diagnostic markers for bipolar I disorder

Mayo Clinic investigators discover potential diagnostic markers for bipolar I disorder

Mayo Clinic researchers have discovered a series of proteins that could be diagnostic markers to identify bipolar I disorder. If this discovery sample can be validated through replication these markers may help as a diagnostic tool for psychiatrists treating mood disorders. [More]
Researchers find lower levels of omega-3 fatty acids in people with bipolar disorder

Researchers find lower levels of omega-3 fatty acids in people with bipolar disorder

People with bipolar disorder have lower levels of certain omega-3 fatty acids that cross the blood-brain barrier compared to those who do not, according to researchers from Penn State College of Medicine and the National Institutes of Health. The finding could have implications for dietary interventions for the disorder. [More]
Atypical antipsychotic shows bipolar I depression efficacy

Atypical antipsychotic shows bipolar I depression efficacy

The atypical antipsychotic cariprazine may be effective for the treatment of bipolar I depression, phase II study findings show. [More]
Lithium can be safe, effective for children suffering from bipolar disorder

Lithium can be safe, effective for children suffering from bipolar disorder

A multicenter study of young patients with bipolar disorder provides what may be the most scientifically rigorous demonstration to date that lithium -- a drug used successfully for decades to treat adults with the condition -- can also be safe and effective for children suffering from it. [More]

Antidepressants can increase depression, mood cycling in rapid-cycling bipolar disorder patients

In patients with rapid-cycling bipolar disorder, antidepressants can increase incidents of depression and mood cycling. Rif S. El-Mallakh, M.D., director of the Mood Disorders Clinical and Research Program at the University of Louisville, along with Nassir Ghaemi, M.D., of Tufts University and other researchers, conducted the first randomized clinical trial that analyzes how modern antidepressants affect patients with rapid-cycling (RC) bipolar disorder (BD). [More]
Why do we sleep? An interview with Professor Wisden

Why do we sleep? An interview with Professor Wisden

It is true that we still do not know why we need to sleep every night. Sleep is essential for health. We have to do it every day. But nobody yet knows why. This fact amazes me. [More]
New report highlights need for accurate diagnosis and management of bipolar I disorder

New report highlights need for accurate diagnosis and management of bipolar I disorder

A new report launched today, ‘Paying the ultimate price’, highlights the urgent need for accurate diagnosis and management of bipolar I disorder in order to address a significant burden on society, patients and carers. [More]

Multi-national study identifies behaviour patterns that precede suicide attempts

A major multi-national study of suicides has identified the behaviour patterns which precede many suicide attempts. This may lead to changes in clinical practice in the care of patients affected with depression, as it shows the clinical factors which confer major risk of suicide attempts. [More]
FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced today the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for review to add clinical data regarding the effect of Brintellix (vortioxetine) on certain aspects of cognitive function in adults with Major Depressive Disorder (MDD) to the current product label. [More]
Mice without specific brain chemical develop characteristics similar to bipolar disorder, shows study

Mice without specific brain chemical develop characteristics similar to bipolar disorder, shows study

Mice that have a particular brain chemical switched off become hyperactive and sleep for just 65 per cent of their normal time. [More]
Allergan announces U.S. availability of SAPHRIS 2.5 mg tablets for children with bipolar I disorder

Allergan announces U.S. availability of SAPHRIS 2.5 mg tablets for children with bipolar I disorder

Allergan plc today announced that SAPHRIS (asenapine) 2.5 mg sublingual (placed under the tongue) black-cherry flavored tablets are available in pharmacies throughout the U.S. In March 2015, the U.S. Food and Drug Administration approved SAPHRIS for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients (ages 10 – 17). [More]
Cognizin citicoline shows promise in patients with bipolar disorder and cocaine dependence

Cognizin citicoline shows promise in patients with bipolar disorder and cocaine dependence

The results of a randomized, double-blind, placebo-controlled clinical trial showed that Cognizin citicoline (Jarrow Formulas) was effective at reducing cocaine use, based on urine drug screens, in patients with bipolar disorder and cocaine dependence. The study, published in the American Journal of Psychiatry in Advance, included a total of 130 outpatients with bipolar I disorder and cocaine dependence, who received either Cognizin citicoline or placebo add-on therapy for 12 weeks. [More]
Advertisement
Advertisement